A carregar...
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
BACKGROUND: One year of adjuvant trastuzumab in combination with chemotherapy is the standard of care in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Existing data on shortening trastuzumab treatment show conflicting results. METHODS: A search of PubMed and abs...
Na minha lista:
| Publicado no: | JNCI Cancer Spectr |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6649709/ https://ncbi.nlm.nih.gov/pubmed/31360906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkz033 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|